跳至主要内容
临床试验/NL-OMON51266
NL-OMON51266
已完成
4 期

The Effect of Enzalutamide on Oxycodone Metabolism in Men with Prostate Cancer - ENZYME

Deventer Ziekenhuis0 个研究点目标入组 27 人待定

概览

阶段
4 期
干预措施
未指定
疾病 / 适应症
未指定
发起方
Deventer Ziekenhuis
入组人数
27
状态
已完成
最后更新
2年前

概览

简要总结

Trial is onging in other countries

注册库
who.int
开始日期
待定
结束日期
2022年9月20日
最后更新
2年前
研究类型
Interventional

研究者

入排标准

入选标准

  • \- Males aged \>\= 18 years;
  • \- Diagnosed prostate cancer;
  • \- Treated with enzalutamide 160 mg once daily for 40 days (arm 1\)

排除标准

  • \- a body mass index (BMI) outside the range of 18 to 30 kg/m2;
  • \- known metastases in the liver that would affect drug metabolism;
  • \- Child\-Pugh classification B or C that would affect drug metabolism;
  • \- known CYP3A4 or CYP2D6 polymorphisms that would affect drug metabolism
  • (patients with a known CYP3A4 or CYP2D6 polymorphism afterwards will be
  • \- known moderate\-severe renal dysfunction (GFR \<60 ml/min/1\.73m2\) that would
  • affect drug metabolism;
  • \- gastrointestinal disorders that would potentially alter absorption;
  • \- previous gastric bypass or gastric band surgery;
  • \- known allergy, hypersensitivity or intolerance to normal\-release oxycodone;

结局指标

主要结局

未指定

相似试验